Cannabis stocks shot up on Monday (August 27) after reports that a massive alcohol producer may enter the space.

Diageo (NYSE:DEO), the alcohol maker behind Guinness beer and Crown Royal Canadian whisky, is eyeing an entry into the booming cannabis market, following in the footsteps of a number of other alcohol companies, a report from BNN Bloomberg says.


Unnamed sources laid out in the report suggest two timeframes for the Diageo move. Some say the company is moving through a long deliberation process that may prove unfruitful in the end. But others have said conversations are moving quickly and that a deal with a Canadian producer is close. 

US Election 2020 and Cannabis

 
Investing in cannabis? Read what experts have to say about cannabis and the US Election!
 

There are two public Canadian cannabis producers with ties in their executive ranks to the alcohol company: Aphria (TSX:APH) and Maricann Group (CSE:MARI).

Aphria’s first-ever chief commercial officer, Jakob Ripshtein, appointed in April, served as a CFO at Diageo Canada. According to his LinkedIn page, he spent eight years with the company.

Another current cannabis executive with a past at the alcohol company is Geoff Kosar, chief marketing officer for Maricann, who was appointed to the cannabis firm in February. Kosar served as marketing director and head of marketing in Canada during his tenure at Diageo, which lasted over eight years.

Market enjoys boost, potential entry adds legitimacy

At the center of all the rumors is Diageo, whose share price rose a marginal 0.35 percent and finished Monday’s trading session at US$141.97.

At market close on Monday, the Horizons Marijuana Life Sciences Index ETF (TSX:HMMJ), which includes close to 40 of the best-known cannabis stocks, was up 5.04 percent. Similarly, the Canadian Marijuana Index, which tracks 17 Canadian cannabis stocks, was up 4.93 percent.

Shares of Aphria shot up following the reported rumors on Friday, closing at C$14.01. On Monday, Aphria opened at C$15.80; the stock went up 6.85 percent to close at C$14.97.

US Election 2020 and Cannabis

 
Investing in cannabis? Read what experts have to say about cannabis and the US Election!
 

Maricann, the other cannabis company with public ties to Diageo, also rose during trading on Friday and Monday, albeit in smaller increments than Aphria. Shares for the CSE-listed producer rose 1.08 percent, reaching a price point of C$1.88 on Monday.

The market’s public favorites on Monday, however, were Cronos Group (TSX:CRON,NASDAQ:CRON) and Tilray (NASDAQ:TLRY), with both increasing over 20 percent.

Cronos, the first Canadian producer to list its common stock on the NASDAQ, had a 21.13-percent increase to finish at US$12.04 on Monday. It had also soared by 20.57 percent on the TSX at the end of trading on Monday. Meanwhile, shares of Tilray rose to US$53.44 thanks to a 21.84-percent increase at the end of Monday’s trading session.

Diageo follows move from fellow alcohol companies

Reports have indicated that alcohol sales are lower in legal cannabis territories. As such, analysts have speculated on when alcohol producers will make a claim for cannabis companies. Other established industries, like tobacco and pharmaceuticals, have also been pointed to as potential players in the space.

Last year, Constellation Brands (NYSE:STZ) made the first move and invested C$245 million into Canopy Growth (TSX:WEED,NYSE:CGC). On August 15, the alcohol company, which produces Corona beer, announced another investment into the cannabis giant.

“We view this investment in our business as an endorsement of our execution since forming our initial strategic relationship in October 2017,” Bruce Linton, co-CEO of Canopy Growth, said following the C$5-billion investment into his company.

The investment from Constellation also sent cannabis stocks off to the races and was described by Charles Taerk, president and CEO of Faircourt Asset Management, as a “shot in the arm” for the industry.

“It legitimizes the Canadian businesses and it legitimizes global recreational and medical opportunities and then you ask the question ‘ok who’s next?’ … that is really a list of companies that we feel are well positioned, have capacity and don’t have a dance partner, so it’s potential,” Taerk said.

Molson Coors Brewing (TSX:TPX.B,NYSE:TAP) also made a play for the public cannabis space by forming a joint venture with the Hydropothecary Corporation (TSX:HEXO) in early August.

The two companies will oversee the standalone company, which is set to work on the production of non-alcoholic beverages infused with cannabis.

Investor takeaway

As investors brace for the impact a potential entry from Diageo would cause in the public cannabis space, rumors have started on which company will be the winner of a deal with the alcohol giant.

Based on its previous involvement with Constellation, Deepak Anand, vice president of Cannabis Compliance, said in an interview that he thinks it’s safe to rule Canopy out of this conversation.

It will be key for investors to follow if the new deal from Diageo comes soon, and if it will lift the entire sector like the Constellation investment did.

Don’t forget to look for our coverage of MJBizCon INT’L, with show notes from the floor and exclusive interviews on INN. You can also follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: Maricann Group is a client of the Investing News Network. This article is not paid-for content.

PharmaTher Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“PharmaTher”) (CSE: PHRM) and a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to provide a corporate update on its psychedelic pharmaceuticals program. Since its inception, the Company has built a unique product pipeline for novel uses of ketamine, psilocybin and undisclosed psychedelics. PharmaTher is positioning itself to partner its psilocybin program and panaceAI™, and focus on advancing its novel ketamine product pipeline in Parkinson’s disease, depression and pain via the U.S. Food and Drug Administration (“FDA”) regulatory pathway.

“We have made tremendous progress over the last several months that saw our product pipeline evolve to focus on the massive opportunity and potential of ketamine, an FDA approved drug with a known safety profile, to treat significant unmet medical needs for Parkinson’s disease, depression and pain,” said Fabio Chianelli, CEO of PharmaTher. “With our focus on ketamine through repurposing, combining it with an FDA approved drug and delivering it with our novel microneedle delivery system, we are now positioned to expedite our clinical development objectives by taking advantage of the FDA’s 505(b)(2) regulatory pathway and commercializing disruptive ketamine treatments for mental health and pain disorders.”

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN), Aurora Cannabis (NYSE: ACB)(TSX: ACB), and Canopy Growth Corporation (NASDAQ: CGC) (TSX: WEED).

Cannabis leaders are focusing on innovation in premium branding, global expansion, and tight operational execution in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders:

Keep reading... Show less

Progressive Planet Solutions Inc. (TSXV: PLAN) (“PLAN” or “Progressive Planet”), an emerging leader in reducing the carbon footprint of cement products using natural pozzolans, is pleased to announce it has sold and optioned a combined total of 10 million of its 10.5 million shares of Snow Lake Resources.

The sale and option agreements were made with two arms-length purchasers. The first sale was for 1,700,000 shares at $0.04 per share for a total of $68,000 and includes an option granted by PLAN entitling the same party to purchase an additional 4,966,666 shares at $0.04 per share until May 11, 2021 . The second sale was for 1,250,000 shares at $0.04 per share for a total of $50,000 and includes an option granted by PLAN to such party to purchase an additional 2,083,334 shares until August 14, 2021 . As at the date of this news release, PLAN has received $116,000 and will receive another $284,000 if the remaining shares are purchased under the option agreements.

Keep reading... Show less

First Products to Hit California Shelves in Q2 2021

 4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) is pleased to announce that its fully funded state of the art 185,000 square foot production facility in Commerce, California is nearing completion and will be ready to serve the $3b California cannabis market in Q2 2021. The project is on target to be completed in April 2021 with the Company planning for the first of its full line of edibles, tinctures and vape products to be on California retail shelves by May.

Keep reading... Show less

MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the “Company”, “MustGrow”) is pleased to announce its upcoming investor awareness initiatives. MustGrow continues to actively engage its key stakeholders – potential industry partners, shareholders and prospective investors – by increasing awareness of its remarkable natural mustard-derived crop protection products.

TODAY: The Future of Food Investment Conference – SnowCap Ventures
Tuesday, Nov. 24th at 1:50 pm ET
Investors Register Here

Keep reading... Show less